Pharmaron Beijing Revamps Governance Roles and Formalizes Registered Capital Increase

Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an update.

Pharmaron Beijing announced a management reshuffle, with company secretary and authorised representative Mr. Yim Lok Kwan resigning effective March 30, 2026, and experienced governance professional Ms. Mak Po Man Cherie stepping in as company secretary, authorised representative and process agent. The board thanked Mr. Yim for his service and highlighted Ms. Mak’s more than 20 years of audit, accounting, corporate finance, compliance and corporate secretarial experience.

The company also moved to formalize a capital structure expansion following a recent placement of 58,440,762 new H shares and the vesting of 647,341 restricted A shares under its share incentive schemes. It plans to increase registered capital from RMB 1,778,195,525 to RMB 1,837,283,628 and amend its articles of association accordingly, with the changes subject to shareholder approval at the AGM and completion of regulatory filings, underscoring its ongoing use of equity financing and incentives to support growth and align employees and investors.

The most recent analyst rating on (HK:3759) stock is a Hold with a HK$21.50 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.

More about Pharmaron Beijing Co., Ltd. Class H

Pharmaron Beijing Co., Ltd. is a China-based contract research and development organization serving the pharmaceutical and biotech industries. The company provides integrated R&D and manufacturing services across the drug discovery and development value chain, with a focus on supporting global clients through both A share and H share listings in mainland China and Hong Kong.

YTD Price Performance: -5.41%

Average Trading Volume: 6,401,070

Technical Sentiment Signal: Sell

Current Market Cap: HK$50.1B

For detailed information about 3759 stock, go to TipRanks’ Stock Analysis page.